Elevated Healthcare Resources Utilization and Costs among Individuals Diagnosed with Rett syndrome (P13-9.004)

Abstract

<h3>Objective:</h3> Compare the HCRU and medical costs of children with and without Rett syndrome. <h3>Background:</h3> No studies have examined the healthcare resource utilization (HCRU) and costs of individuals diagnosed with Rett syndrome using a commercially available dataset. <h3>Design/Methods:</h3> A retrospective cohort study examined individuals diagnosed with Rett compared to a control sample on HCRU and costs during the 12-months following index. Study data (2017–2022) were integrated medical claims from Clarivate. Index was defined as the initial Rett Dx, or medical claim on record during the case-finding period among individuals in the Rett and control cohorts, respectively. Outcomes were HCRU and cost (per patient per year, PPPY). <h3>Results:</h3> Eligibility criteria identified 1,046 individuals diagnosed with Rett and 2,157 in the control cohort. All-cause healthcare visits totaled 24.7 vs. 8.3 PPPY (p&lt;0.05) among the Rett and control cohorts, respectively. The Rett cohort averaged 3-fold more PCP visits (15.0 vs. 4.9, p&lt;0.05). Similar differences were observed for non-PCP outpatient visits (Rett: 6.3 vs. control: 2.2, p&lt;0.05). Inpatient admissions were 7.3-fold higher among the Rett compared with the control cohort (2.2 vs. 0.3, p&lt;0.05). ED visits were also higher (1.2 vs. 0.9, p&lt;0.05). Other medical services used, which included medical equipment, labs etc., were 20-fold higher among the Rett cohort (42.1 vs. 2.1, p&lt;0.05). Healthcare utilization patterns translated into higher medical costs for the Rett cohort vs. controls. Total medical costs were 20-fold higher among the Rett cohort PPPY ($25,926.30 vs. $1,611.00, p&lt;0.05). Cost differences between cohorts were driven by other medical services used ($19,384.20 vs $437.80, p&lt;0.05) although all cost categories were higher and statistically different for the Rett and control cohort. <h3>Conclusions:</h3> HCRU and costs among individuals diagnosed with Rett are substantially higher relative to other children in the US and may result in considerable financial burden for parents and caregivers. <b>Disclosure:</b> Dr. Davis has received personal compensation for serving as an employee of Health Analytics,LLC. The institution of Dr. Davis has received research support from Acadia Pharmaceuticals . Dr. Parab has received personal compensation for serving as an employee of Health Analytics, LLC.. The institution of Dr. Parab has received research support from Acadia. Dr. May has received personal compensation for serving as an employee of Acadia Pharmaceuticals. Dr. May has stock in ACADIA Pharmaceuticals. Dr. May has stock in Medtronic. Dr. May has stock in Johnson &amp; Johnson. Dr. May has stock in Pfizer Pharmaceuticals. The institution of Dr. Ruetsch has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Otsuka Amrerica. The institution of Dr. Ruetsch has received research support from Otsuka America. The institution of Dr. Ruetsch has received research support from Acadia. The institution of Dr. Ruetsch has received research support from Atentiv. The institution of Dr. Ruetsch has received research support from GSK. The institution of Dr. Ruetsch has received research support from Medtronic. The institution of Dr. Ruetsch has received research support from Novartis. The institution of Dr. Ruetsch has received research support from Orexo.